SERANasdaqServices-Medical LaboratoriesFiscal year ends December 31

SERA PROGNOSTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$2.03−0.03 (-1.46%)

Close on Oct 19, 2026

Market cap: $102.47M
P/E (TTM): –
Dividend yield: –

SERA PROGNOSTICS, INC. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Depreciation & Amortization	0.94	0.83	0.90	0.76	0.66	0.90
Stock-Based Compensation	5.11	7.01	5.27	5.06	3.13	0.73
Deferred Income Taxes	0	0	0	0	0	0
Other Non-Cash Items	0.01	0.07	-0.02	0.02	-0.09	-0.08
Change in Accounts Receivable	0.02	0.13	-0.05	-0.09	-0.03	0.00
Change in Accounts Payable	-1.01	0.46	-0.44	0.35	0.60	-0.31
Change in Unearned Revenue	0.09	-0.01	11	5.97	3.12	0
Operating Cash Flow	-26	-14	-27	-35	-32	-17
Capital Expenditures	-0.73	-0.06	-0.13	-0.79	-1.30	-0.15
Sale of Property, Plant & Equipment	–	0	0.31	0.02	0	–
Purchase of Investments	-88	-36	-54	-48	-82	0
Sale & Maturity of Investments	60	49	54	54	0.80	0
Investing Cash Flow	-29	12	0.44	5.55	-83	-0.15
Stock Issued	54	–	–	–	–	–
Debt Issued	–	–	–	–	0	1.05
Debt Repaid	–	–	–	0	-3.10	0
Financing Cash Flow	54	2.61	0.75	0.01	160	9.16
Free Cash Flow	-26	-14	-27	-35	-33	-17
Interest Paid	0.01	0.03	0.06	0.05	1.19	0.25

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: -150.0%
Operating margin: -53282.9%
Net margin: -47475.7%
Return on equity, FY2025: -51.8%

Financial strength

Current ratio: 1.98
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 18.1%

Valuation

P/E ratio: –
Price to sales: 1463.83
Price to book: 1.73
Dividend yield: –